New pivotal data demonstrate clinical benefit of Roche ’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma

Data to be presented for the first time at ASCO and EHA 2022 showglofitamab induces high and durable complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma1Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphomaGlofitamab is part of Roche ’s industry-leading CD20xCD3 bispecific antibody developmentprogramme, which aims to address the diverse needs and preferences of people with blood cancersBasel, 27 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from 3-7 June and the European Hematology Association (EHA) 2022 Congress from 9-12 June. Data from the phase II NP30179 expansion study demonstrated that, after a median follow-up of more than 12 months, fixed-duration glofitamab (given for a fixed amount of time, and not taken until disease progression) induces durable complete responses (CRs) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who had received a median of three prior therapies.1“These data bring us one step closer towards our goal of finding solutions for people with heavily pre-treated diffuse large B-cell lymphoma, which often relapses and becomes more aggressive each ti...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news